Insights

More Articles Back to Article

EMA to accelerate review of AZ, Daiichi Sankyo HER2 drug Enhertu

The European Medicines Agency will fast-track its review of AstraZeneca and Daiichi Sankyo's HER2-positive breast cancer candidate Enhertu, or trastuzumab deruxtecan. The FDA approved the antibody drug conjugate as a treatment for metastatic HER2-positive disease in December. PMLive (UK) (7/7)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!